In the context of GBM, CD4+ T cell immunosenescence has been associated with poor clinical outcomes: patients with elevated levels of CD4+CD28−CD57+ T cells exhibit significantly reduced overall survival [110]. The gene discussed is CD4; the disease is glioblastoma.